Arvid Rongve
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Year:
2026
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 2050 1 . AD is highly heritable, with twin-based heritability estimates of 60-80% 2 . While 1,200 causal loci are predicted to exist for AD 3 , approximately 80 have been associated with AD in two recent studies 4,5 , suggesting that many loci remain to be discovered 6 . Here, we analyzed data from 183,620 AD cases and 2.6 million controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and identified microglia and, for the first time, several neuronal cell types enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a single-nucleotide polymorphism (SNP) heritability of 19%. Together, our findings offer insights into the genetic architecture and potential pathobiology of AD, as well as specific targets for future drug development research.
Year:
2025
Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.
Year:
2025
Background and objectives Detecting Alzheimer’s disease (AD) biological and clinical changes is crucial for early diagnostic and therapeutic interventions. Here we investigate the relationship between clinical severity and levels of phosphorylated tau, focusing on plasma biomarkers, in preclinical and prodromal AD. Methods In this study (n=621), we examined two independent cohorts consisting of preclinical and prodromal AD. Cohort-1 included 431 participants classified as either cognitively normal (CN) or mild cognitive impaired (MCI) with normal or abnormal cerebrospinal fluid (CSF) Aβ42/40 ratio (A) and p-tau181 (T) [CN A-/T-, n=169; A+/T-, CN=26; MCI=24; A+/T+, CN=40; MCI=105; CN=34; MCI=33]. A total of n=418 of the participants had longitudinal assessments of verbal memory up to 9.67 years from baseline. Cohort-2 included 190 participants in whom amyloid status was determined using Aβ positron emission tomography (PET) [Aβ- CN= 118; Aβ+ CN= 49; Aβ+ MCI= 21]. Results In cohort-1, plasma p-tau217 showed a moderate correlation with its corresponding CSF biomarker (rho=0.65, p<.001) and high accuracy identifying Aβ+ participants (AUC: 0.85). Diagnostic accuracy of plasma p-tau217 was significantly greater for MCI Aβ+ (AUC: 0.89) versus CN Aβ+ (AUC: 0.79, p<.05) and for A+/T+ (AUC: 0.88) versus A+/T- (AUC: 0.78, p<.05). P-tau181 and p-tau231 showed significantly weaker CSF-plasma correlations (rho= 0.47, and rho=0.32, p<.001, respectively) and levels were not as tightly associated with cognitive status in the Aβ+ group. While all the CSF p-tau markers were associated to future cognitive deterioration, p-tau217 was the only plasma biomarker associated with future memory decline (β=0.05, p<0.05). In cohort 1 and 2, plasma p-tau217 showed significantly higher concentrations in MCI Aβ+ as compared to CN Aβ+. Furthermore, plasma p-tau217 demonstrates similar biomarker elevations when compared to CN Aβ- controls in both cohorts. Discussion Our findings indicate that, unlike p-tau181 and p-tau231, plasma p-tau217 consistently aligns with cognitive status in Aβ+ individuals and more closely reflects CSF biomarker abnormalities, potentially reducing discrepancies between clinical and biochemical findings. The associations of plasma p-tau217 with baseline and future cognitive decline make it a valuable complement to clinical evaluations in preclinical and prodromal AD, especially when CSF analysis or PET are not feasible.
Year:
2024
Collaborators (69)
Ruth Frikke-Schmidt
Professor, Chief Physician, MD PhD DMSc
-
Pau Pastor
Institut Català de la Salut
Eloy Rodriguez-Rodríguez
Instituto de Investigación Marqués de Valdecilla
innocenzo rainero
University of Turin
Agustín Ruiz Laza
Director of the Biology Core
University of Texas Health Science Center at San Antonio
Harro Seelaar
Neurologist
Erasmus MC
Paul O'Reilly
Associate Professor
Icahn School of Medicine at Mount Sinai
Philippe Amouyel
Full Professor
Centre Hospitalier Régional Universitaire de Lille
Jesper Qvist Thomassen
Senior Scientist
Rigshospitalet
Clive Ballard
Pro-Vice Chancellor and Executive Dean
University of Exeter
Henne Holstege
Professor
KU Leuven
Marco Spallazzi
Adjunt professor
University of Parma
Benedetta Nacmias
University of Florence
Lucilla Parnetti
Professor of Neurology
University of Perugia
Caroline Jonson
University of California, San Francisco
Pieter Jelle Visser
Karolinska Institutet
Jordi Pérez-Tur
Coordinador Adjunto al Área Global Vida
Agencia Estatal Consejo Superior de Investigaciones Científicas
Patrizia Mecocci
Director
Karolinska Institutet
Caroline Graff
Professor,MD PhD
Karolinska Institutet
Henna Martiskainen
University of Eastern Finland
Amy Kit Yu Fu
Research Professor
The Hong Kong University of Science and Technology
Jean-Charles Lambert
Head of research unit
INSERM
Betty Tijms
Senior researcher
VU medisch centrum
Nancy Yuk-Yu Ip
The Morningside Professor of Life Science
The Hong Kong University of Science and Technology
Katja Scheffler
Associate Professor
Norwegian University of Science and Technology
Geert Jan Biessels
Professor of Neurology
University Medical Center Groningen
Sara Hägg
Senior Researcher
Karolinska Institutet
Takeshi Ikeuchi
Professor
Brain Research Institute, Niigata University
Mohsen Ghanbari
Associate professor
Erasmus MC
Geir Selbaek
Professor
University of Oslo
Lasse Pihlstrøm
Professor
University of Oslo
Byron Creese
Senior Lecturer & Director of Research
Brunel University London
Chandra A Reynolds
Professor
University of Colorado Boulder
Pablo Mir
-
Tormod Fladby
Professor ll of Neurology
University of Oslo
Jens Hjerling Leffler
Karolinska Institutet
Thomas Truelsen
University of Copenhagen
Srdjan Djurovic
Senior Researcher
University of Oslo
Christian Erikstrup
Chair Professor
Aarhus University
Sami Heikkinen
Research Director
University of Eastern Finland
Najaf Amin
Associate Professor
University of Oxford
Wiesje van der Flier
Scientific director
VU medisch centrum
Peter Holmans
Professor of Biostatistics and Genetic Epidemiology
Cardiff University
Alessandro Serretti
Docenti di ruolo di IIa fascia
Università degli Studi di Enna Kore
Bjørn-Eivind Kirsebom
UiT The Arctic University of Norway
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
Alessio Squassina
Dalhousie University
Carole Dufouil
Director of research
INSERM
Martin Ingelsson
Specialist
Uppsala University Hospital
Gael Nicolas
PUPH
University of Rouen
D.P. Wightman
University of Amsterdam
Anssi Lipponen
University of Eastern Finland
Patrick Kehoe
Academic , Gestetner Professor of Translational Dementia Research
University of Bristol
Thomas Folkmann Hansen
Professor
Technical University of Denmark
Fernando Gonzalez-Ortiz
University of Gothenburg
INGVILD SALTVEDT
Professor
Norwegian University of Science and Technology
Morten Fjeld
Professor
University of Bergen
Jian Zeng
The University of Queensland
Dag Aarsland
Professor and Head of Department
King’s College London
Daniela Galimberti
Associate Professor
Università degli Studi di Torino
Ole A. Andreassen
Oslo University Hospital
Lucio Tremolizzo
Associate Professor of Neurology
University of Milano-Bicocca
Valentina Escott-Price
Professor
Cardiff University
Ville Leinonen
Professor
University of Eastern Finland
Rebecca Sims
Senior Research Fellow
Cardiff University
Barbara Borroni
Docenti di ruolo di IIa fascia
University of Brescia
Jose Luis Royo
University of Malaga
Mikko Hiltunen
University of Eastern Finland
Frank J. Wolters
Associate professor
Erasmus University Rotterdam
Make your next move.
Prepare your application
Review drafts before you send them.